NEW YORK (GenomeWeb News) – Anil Potti, the Duke University cancer researcher who falsely claimed he was a Rhodes Scholar and who is accused of faking some cancer research, has resigned from the school.
Huntington Willard , director of Duke’s Institute for Genome Sciences and Policy, confirmed the resignation in an e-mail to the institute's staff.
In it, Willard said that Potti has accepted "full responsibility for a series of anomalies in data handling, analysis, and management that have come under scrutiny in the past months."
Willard added that "the various investigations" into the charges leveled against Potti "will continue, as will our own efforts in the IGSP to review and evaluate the science in question."
Earlier this week, the Journal of Clinical Oncology retracted a 2007 article by Potti and co-researchers, at the request of Duke researcher and Potti collaborator, Joseph Nevins, because the authors could not reproduce the results from the experiment.
Eurogentec has appointed Marc Molina to take on the post of global IVD business development director. He is replacing the departing Peter Haima, who has held the job since 2006. Molina comes to Eurogentec from Stago Corporation, where he also was business development executive. Molina will be based at the firm's headquarters in Liege, Belgium.
On-Q-ity has appointed Walter Carney to serve as chief scientific officer. Most recently CEO of Oncogene Science, in his new position Carney will oversee all of the firm's personalized cancer diagnostics research programs. Carney also currently is an assistant clinical professor in the Department of Pathology at Tufts Medical Center.
NorDiag said in its quarterly earnings report this week that it has hired Timothy Murray and Guttorm Osborg.
Murray began serving as GM this week. He has worked in sales and marketing at Luminex, Sequenom's Center for Molecular Medicine, Cenetron, and Bayer Diagnostics.
Osborg will join the company at the beginning of 2011 as VP of Instruments and Automation after serving as director of development, production, and service of instruments at Axis Shield.
Genomic Health Co-founder Patrick Terry will join Scientia Advisors as a principal in the firms' pricing and reimbursement and market access practice. Terry also founded the Personalized Medicine Coalition, the European Personalized Medicine Association, and the Coalition for 21st Century Medicine. At Scientia, Terry will launch and manage pricing, reimbursement, and access in the company's North American and European market operations. This new practice at the company will primarily focus on helping companies in therapeutics, diagnostics, and medical device fields develop and implement reimbursement and pricing strategies.
Yuan Gao has been appointed director of genomics, epigenomics, and bioinformatics at the newly founded Lieber Institute for Brain Development in Baltimore. Gao is also a founding faculty member of the institute. Previously, Gao was an assistant professor at the Center for the Study of Biological Complexity and the department of computer science at Virginia Commonwealth University.